get a key
steadybase-$ company SPRY
account_id none on file
legal_name ARS Pharmaceuticals, Inc.
ticker SPRY
cik 1671858
domain ars-pharma.com
entry_point_account_id none on file
name ARS Pharmaceuticals Inc.
exchange Nasdaq
sector Health Care
calls 1 filings 0 executives 5 family 0
why_nownone on file
calls
As Rich said, you know, we looked across the entire marketing kind of commercial budget, and the things that we're taking down, like we looked last year at some of the large conferences, some of the regional conferences that we did, and we really did an analysis of the greatest impact in terms of And as Rich also said, we look to optimize kind of our spend from a media perspective, so some money from there. And then also just monies that the representatives use in the offices to bring in, you know, lunch and things along those lines, a very small portion. But, again, we feel very confident that this does not have any impact on our ability to execute what we need to do, but more important, pull through and the frequency that we see that really links to higher market share adoption is what we're excited about.

Mar 9, 2026 / receipt, needs a key / Eric, other | earnings call 2026-03-09 | transcript 23088f87-0389-419b-8ff7-cdc395e0a344 | chars 22282-23101 | segment 23

filingsnone on file
executives
Brian T. Dorsey Chief Operations Officer - receipt
Donn Casale President - receipt
Eric Karras Chief Commercial Officer - receipt
Kathy Scott Chief Financial Officer linkedin receipt
Richard Lowenthal CEO - receipt
familynone on file
upcoming
2026-11-09 earnings call scheduled ir
changes
2026-05-13 President, appointed sec_8k
2022-12-09 Chief Operations Officer, appointed sec_8k
mcp_package_hint
steadybase-$